CasNo.366789-02-8,factory supply 98% Rivaroxaban Form I powder,(366789-02-8) Suppliers

1 Kilogram	FOB Price:USD 1.0000 -999.0000

Min.Order :1 Kilogram
Purity: 98% up
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Rivaroxaban Form I 98% up factory supply

Quick Details

Appearance:White powder
Application:Medicine Grade
PackAge:1kg/bag ;5kg/drum:25KG/drum
ProductionCapacity:20|Metric Ton|Month
Storage:in low tempreture
Transportation:in low tempreture

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier .

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Why choose us

Our advantages of Rivaroxaban (CAS:366789-02-8) ^:
1. Quality: Form I,assay 98% up ,conform to USP/EP standard ,

2. Normal PSD D90＜100um & Micron PSD D90 ＜10um.

3. Documents: local GMP,WC and DMF. CEP is under applying. The price with documents is higher than without.
4. Large capacity & stock : 120~180kg per month with 800kg in stock for prompt shipment
5. Better payment terms : We can make use of Export Credit Insurance after confirming yr credit report accepted by Sinosure, accept Alibaba Trade Assurance
6. Various shipping ways for your choice : by air./ by sea / by courier (DHL/FedEx).

Details:

Product Information

Product name	Rivaroxaban
CAS No.	366789-02-8
Molecular Formula	C19H18ClN3O5S
Molecular Weight	435.8813
Quality Standard	98% up, Medicine Grade
Appearance	White powder

COA of Rivaroxaban

TEST	SPECIFICATION	RESULTS
Appearance	White to off-white powder	White powder
Identification	A: The infrared absorption of rivaroxaban corresponds to reference standards	Conforms
	B: The retention time of the main peak of the sample solution corresponds to that of the system suitability solution, as obtained in the enantiomeric purity	Conforms
ENANTIOMERIC PURITY	RVX RC01: NMT 0.15%	None detected
WATER (KF)	NMT 0.5%	0.2%
SULPHATED ASH	NMT 0.1%	0.02%
ACETIC ACID	NMT 5000 ppm	774 ppm
RELATED SUBSTANCES(HPLC)	RVX RC02: NMT 0.15%	None detected
	RVX RC03: NMT 0.15%	None detected
	RVX RC04: NMT 0.15%	None detected
	RVX RC05: NMT 0.15%	0.04 %
	RVX RC06: NMT 0.15%	< disregard limit (0.03%)
	RVX RC07: NMT 0.15%	None detected
	RVX RC08: NMT 0.15%	None detected
	Any other individual impurity: NMT 0.10%	0.07%
	Total impurities: NMT 0.5%	0.15%
RESIDUAL SOLVENTS (GC)	Ethanol: NMT 5000 ppm	26 ppm
	Toluene: NMT 890 ppm	None detected
	Triethylamine: NMT 320 ppm	None detected
ASSAY	NLT 98.0% & NMT 102.0% (on anhydrous basis)	100.1%
STORAGE	Preserved in tight and light resistant container Temperature: ≤ 30^。C
CONCLUSION	The product complies with the specification of In-house standard

Usage

Function of Rivaroxaban

Rivaroxaban is an oral, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) to exert its activity. Factor X is activated by endogenous and exogenous pathways as factor Xa (FXa), which plays an important role in the coagulation cascade.

1. Rivaroxaban is for adult patients with elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Rivaroxaban is used to treat adult venous thrombosis (DVT) and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. Rivaroxaban is for adult patients with non-valvular atrial fibrillation with one or more risk factors (for example: congestive heart failure, hypertension, age ≥75 years, history of diabetes, stroke or transient ischemic attack), to Reduce the risk of stroke and systemic embolism.

In the condition of well-controlled treatment with warfarin, there are limited data on the relative effectiveness of rivaroxaban in reducing the risk of stroke and systemic embolism compared with warfarin.